Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis

References

• BurdettSPignonJPTierneyJAdjuvant chemotherapy for resected early-stage non-small cell lung cancerCochrane Database Syst Rev20157SupplCD011430
   Google Scholar
• GoldstrawPCrowleyJChanskyKThe IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumoursJ Thorac Oncol20072870671417762336
   PubMed Web of Science ®Google Scholar
• ArriagadaRBergmanBDunantACisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancerN Engl J Med2004350435136014736927
   PubMed Web of Science ®Google Scholar
• WintonTLivingstonRJohnsonDVinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancerN Engl J Med2005352252589259715972865
   PubMed Web of Science ®Google Scholar
• DouillardJ-YRosellRde LenaMAdjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trialLancet Oncol20067971972716945766
   PubMed Web of Science ®Google Scholar
• MokTSWuY-LThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• ZhouCWuY-LChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (optimal, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• HanJ-YParkKKimS-WFirst-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• WuY-LZhouCHuC-PAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• YangJCWuY-LSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• GossGDO’CallaghanCLorimerIGefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 studyJ Clin Oncol201331273320332623980091
   PubMed Web of Science ®Google Scholar
• KellyKAltorkiNKEberhardtWEEAdjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (radiant): a randomized, double-blind, phase III trialJ Clin Oncol201533344007401426324372
   PubMed Web of Science ®Google Scholar
• WuYLZhongWWangQGefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage IIIIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (adjuvant): a randomized, phase III trial (CTONG 1104)J Clin Oncol201735158500
   Google Scholar
• YueDXuSWangQErlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (Evan): a randomised, open-label, phase 2 trialLancet Respir Med201861186387330150014
   PubMed Web of Science ®Google Scholar
• FengSWangYCaiKRandomized adjuvant chemotherapy of EGFR-mutated non-small cell lung cancer patients with or without Icotinib consolidation therapyPLoS One20151010e014079426474174
   PubMed Web of Science ®Google Scholar
• LvCAnCFengQA retrospective study of stage I to IIIA lung adenocarcinoma after resection: what is the optimal adjuvant modality for patients with an EGFR mutation?Clin Lung Cancer2015166e173e18125958850
   PubMed Web of Science ®Google Scholar
• NealJWNaPGovindanRThe select study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)J Clin Oncol20123015_suppl7010
   Web of Science ®Google Scholar
• LuDNieXWanJIs off-pump coronary artery bypass grafting superior to drug-eluting stents for the treatment of coronary artery disease? A meta-analysis of randomized and nonrandomized studiesInt J Cardiol2014174364065324814900
   PubMed Web of Science ®Google Scholar
• StangACritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEur J Epidemiol201025960360520652370
   PubMed Web of Science ®Google Scholar
• HigginsJPTGreenSCochrane CollaborationCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]Hoboken, NJWiley-Blackwell2008
   Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• ParmarMKTorriVStewartLExtracting summary statistics to perform meta-analyses of the published literature for survival endpointsStat Med19981724281528349921604
   PubMed Web of Science ®Google Scholar
• ZhongW-ZWangQMaoW-MGefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyLancet Oncol201819113914829174310
   PubMed Web of Science ®Google Scholar
• LiNOuWYeXPemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II studyAnn Surg Oncol20142162091209624585406
   PubMed Web of Science ®Google Scholar
• D’AngeloSPJanjigianYYAhyeNDistinct clinical course of EGFR -Mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinibJ Thorac Oncol20127121815182223154553
   PubMed Web of Science ®Google Scholar
• JanjigianYYParkBJZakowskiMFImpact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutationsJ Thorac Oncol20116356957521150674
   PubMed Web of Science ®Google Scholar
• YuanYHuangQGuCChenHDisease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysisJ Thorac Dis20179125314532129312741
   PubMed Web of Science ®Google Scholar
• HuangQLiJSunYWangRChengXChenHEfficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysisChest201614961384139226836897
   PubMed Web of Science ®Google Scholar
• HeJShenJYangCAdjuvant chemotherapy for the completely resected stage IB nonsmall cell lung cancer: a systematic review and meta-analysisMedicine20159422e90326039122
   PubMed Web of Science ®Google Scholar
• StraussGMHerndonJEMaddausMAAdjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy Oncology group, and North Central cancer Treatment Group study groupsJ Clin Oncol200826315043505118809614
   PubMed Web of Science ®Google Scholar
• WoodardGAWangSXKratzJRAdjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancerClin Lung Cancer2018191586428645632
   PubMed Web of Science ®Google Scholar
• AgarwalMBrahmandayGChmielewskiGWWelshRJRavikrishnanKPAge, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resectionLung Cancer201068339840219762109
   PubMed Web of Science ®Google Scholar
• KrisMGGasparLEChaftJEAdjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: american Society of clinical Oncology/ Cancer care Ontario clinical practice guideline updateJ Clin Oncol201735252960297428437162
   PubMed Web of Science ®Google Scholar
• NygaardADHoldgaardPCSpindlerK-LGPallisgaardNJakobsenAThe correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLCBr J Cancer2014110236336824231948
   PubMed Web of Science ®Google Scholar
• AlegreEFuscoJPRestitutoPTotal and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic valueTumour Biol20163710136871369427473086
   PubMedGoogle Scholar
• XmYYcWLiuXCell-free RNA content in peripheral blood as potential biomarkers for detecting circulating tumor cells in non-small cell lung carcinomaInt J Mol Sci20161711E184527827952
   PubMed Web of Science ®Google Scholar
• WeiZWangWShuZZhouXZhangYCorrelation between circulating tumor DNA levels and response to tyrosine kinase inhibitors (TKI) treatment in non-small cell lung cancerMed Sci Monit2017233627363428742791
   PubMed Web of Science ®Google Scholar
• LeeYParkSKimWSCorrelation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR -mutated non-small cell lung cancerThorac Cancer2018991104111029989342
   PubMed Web of Science ®Google Scholar
• ZhongW-ZZhaiH-RWuY-LClinical trials in lung cancer surgery and research cooperationChin Clin Oncol2014344625841527
   PubMedGoogle Scholar